English Translation on Report

7:04 S 2 5GUC .ll 77% 4 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited accept no responsibility for the contents of this announcement and make no representation as to its accuracy or completeness and expressly disclaim any liability for any loss arising from or in reliance on the whole or any part of this announcement. This announcement is for informational purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. (H) CHINA HEALTH China Health Technology Group Holding Company Limited (incorporated in the Cayman Islands with limited liability) (stock code: 1069) has lapsed the placing of new shares under a general mandate, and reference is hereby made to China Health Technology Group Holdings Limited (the "Company") dated 28 May 2024, The contents of the announcements dated 31 May 2024 and 18 June 2024 were in relation to the placing of new shares under general mandate (the "Announcements"). Unless otherwise defined, terms used in this Notice shall have the same meanings as defined in those Notices. The Board announced that the conditions under the Placing Agreement could not be met by 5 July 2024. As a result, the Placing Agreement became unconditional and expired on 5 July 2024. Pursuant to the Placing Agreement, all obligations and liabilities of its parties in respect of the Placing will cease and terminate and no claim shall be made against the other party in respect of any matter arising out of or in connection with the Placing, except in the event of any prior default. The Directors consider that the lapse of the Placing will not have any material adverse effect on the existing business operations and financial condition of the Group. Hong Kong, 8 July 2024 Appointed by the Board of Directors Professor Ling Feng, Chairman and Executive Director of China Health Technology Group Holdings Limited, the Board of Directors comprises Professor Ling Feng and Mr. Wang Yibin, Executive Director; and independent non-executive Directors Mr. Guo Zhonglong, Mr. Zhou Yingnan and Ms. Bi Xue >